HCV基因6型增加亚洲肝硬化患者肝细胞癌风险
这项随访研究纳入851例亚洲患者(222例HCV基因6型,629例其他基因型),评估HCV基因6型的自然史。中位随访4072人年后新发96例肝细胞癌,总发病率为23.6/1000人年。在肝硬化患者中,基因6型较非6型显著增加肝细胞癌风险(调整HR=2.12,95%CI 1.33-3.39,P<0.05)。
要点
- 肝硬化患者中,HCV基因6型较非6型肝细胞癌累积风险为76.2% vs 36.2%(P<0.05)。
- 肝硬化患者中,HCV基因6型与肝细胞癌显著相关,调整HR=2.12(95%CI 1.33-3.39)。
- 无肝硬化患者中,基因6型与非6型肝细胞癌累积风险无显著差异(2.9% vs 2.2%,P=0.45)。
核心结论
- 在肝硬化患者中,HCV基因6型感染者应优先接受抗病毒治疗以降低肝细胞癌风险,并应坚持肝细胞癌监测。
研究设计与样本
- 随访研究,纳入851例亚洲患者,其中222例为HCV基因6型,629例为其他基因型。
主要发现
- 随访4072人年后,新发肝细胞癌96例,发病率为23.6/1000人年。
- 无肝硬化患者中,基因6型 vs 非6型的肝细胞癌累积风险为2.9% vs 2.2%(P=0.45)。
- 肝硬化患者中,基因6型 vs 非6型的肝细胞癌累积风险为76.2%(95%CI 55.6-96.8%) vs 36.2%(95%CI 28.7-39.1%)(P<0.05)。
- 肝硬化患者中,基因6型较非6型肝细胞癌调整HR=2.12(95%CI 1.33-3.39),P<0.05。
- 以基因非1非6型为参照,基因1型和基因6型的肝细胞癌调整HR分别为1.13(95%CI 0.56-2.27)和2.34(95%CI 1.12-4.86)。
临床怎么用
- 作者认为,肝硬化患者中HCV基因6型感染者应优先接受抗病毒治疗以降低肝细胞癌风险,并应坚持肝细胞癌监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hepatitis C virus (HCV) infection is a well-documented risk factor for hepatocellular carcinoma (HCC). Seven HCV genotypes have been classified, and the genotypes show a great variety of geographic distribution. HCV genotype 6 is prevalent in Southeast Asia and has been less studied than the other genotypes. METHODS: This follow-up study was designed to evaluate the natural history of HCV genotype 6. The cohort enrolled 851 Asian patients consisting of 222 with HCV genotype 6 and 629 with other genotypes. The incidence of HCC per 1,000 person-years of various HCV genotypes was estimated by dividing the new HCC cases to the person-years of follow-up. The adjusted hazards ratios (HRs) with 95% confidence intervals (CIs) were estimated by Cox's proportional hazards models. RESULTS: After 4072 person-years of follow-up, there were 96 newly-developed HCC cases, confirming an incidence of 23.6 per 1000 person-years. By stratifying cirrhosis at study entry, the cumulative risk of HCC among HCV genotype 6 vs. non-6 was 2.9 vs. 2.2% for those without cirrhosis (P=0.45) and 76.2% (95% CI: 55.6-96.8%) vs. 36.2% (95% CI: 28.7-39.1%) for those with cirrhosis (P<0.05), respectively. Among patients with cirrhosis, HCV genotype 6 was significantly associated with HCC compared to patients with non-6 genotypes, with the adjusted HR=2.12 (1.33-3.39), P<0.05. In a model treating patients with genotypes other than 1 or 6 as the reference, the adjusted HR for HCC for HCV genotypes 1 and 6 were 1.13 (0.56-2.27) and 2.34 (1.12-4.86), respectively. CONCLUSIONS: Among patients with cirrhosis, those with HCV genotype 6 infection should be given high priority for antiviral therapy to decrease HCC risk and for vigilant adherence to HCC surveillance.
引用
- Lee MH, Hsiao TI, Subramaniam SR, et al. HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. Am J Gastroenterol. 2017. PMID: 28440303. doi:10.1038/ajg.2017.123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。